Article date: September 2017
By: Mitsutaka Nishimoto, Hideo Koh, Atsushi Tokuwame, Yosuke Makuuchi, Masatomo Kuno, Teruhito Takakuwa, Hiroshi Okamura, Shiro Koh, Takuro Yoshimura, Satoru Nanno, Mika Nakamae, Asao Hirose, Yasuhiro Nakashima, Takahiko Nakane, Masayuki Hino, Hirohisa Nakamae in Volume 83, Issue 9, pages 2000-2007
Aim
Small‐scale clinical studies have reported on drug interactions between caspofungin (CPFG) and calcineurin inhibitors in healthy subjects; however, little is known about these interactions in allogeneic haematopoietic cell transplantation (allo‐HCT) patients.
Methods
We retrospectively assessed the drug interactions and safety profiles in allo‐HCT recipients treated concomitantly with CPFG and calcineurin inhibitors.
Results
Ninety‐one consecutive cases were evaluated. There were no statistically significant differences in the plasma concentration/dose (C/D) ratios of tacrolimus (TAC) in 34 patients before and after co‐administration with CPFG (median: 575.6–672.4, P = 0.200). In contrast, the median C/D ratio of cyclosporin A (CsA) in 16 patients was significantly elevated after co‐administration with CPFG (median: 62.8–74.9, P = 0.016). There were no serious adverse effects on liver or renal function associated with the therapy.
Conclusions
Our data show that CPFG did not affect the pharmacokinetics of TAC and that it could mildly increase CsA blood concentrations in allo‐HCT patients.
DOI: 10.1111/bcp.13303
View this article